Cargando…
Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system
BACKGROUND: We evaluated the frequency of genomic testing and treatment patterns by age category in patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated in both academic‐ and community‐based health systems within a single Midwestern State. METHODS: Retrospective analysis of data f...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524030/ https://www.ncbi.nlm.nih.gov/pubmed/37635639 http://dx.doi.org/10.1002/cam4.6442 |
_version_ | 1785110663760183296 |
---|---|
author | Byrd, John C. Gatz, Jennifer L. Louis, Cynthia Lim Mims, Alice S. Borate, Uma Yocum, Ashley O. Gana, Theophilus J. Burd, Amy |
author_facet | Byrd, John C. Gatz, Jennifer L. Louis, Cynthia Lim Mims, Alice S. Borate, Uma Yocum, Ashley O. Gana, Theophilus J. Burd, Amy |
author_sort | Byrd, John C. |
collection | PubMed |
description | BACKGROUND: We evaluated the frequency of genomic testing and treatment patterns by age category in patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated in both academic‐ and community‐based health systems within a single Midwestern State. METHODS: Retrospective analysis of data from the Indiana University Health System Enterprise Data Warehouse and two local cancer registries, of 629 patients aged ≥18 years with ND AML during 2011–2018. Primary outcome variables were, proportion of patients with genomic analysis and frequency of mutations. Chemotherapy was categorized as “standard induction” or “other chemotherapy”/targeted therapy, and hypomethylating agents. RESULTS: Overall, 13% of ND AML patients between 2011 and 2018 had evidence of a genomic sequencing report with a demonstrated increase to 37% since 2016. Genomic testing was more likely performed in patients: aged ≤60 years than >60 years (45% vs. 30%; p = 0.03), treated in academic versus community hospitals (44% vs. 26%; p = 0.01), and in chemotherapy recipients than non‐therapy recipients (46% vs. 19%; p < 0.001). Most common mutations were ASXL1, NPM1, and FLT3. Patients ≥75 years had highest proportion (46%) of multiple (≥3) mutations. Overall, 31.2% of patients with AML did not receive any therapy for their disease. This subgroup was older than chemotherapy recipients (mean age: 71.4 vs. 55.7 years, p < 0.001), and was highest (66.2%) in patients ≥75 years. CONCLUSIONS: Our results highlight the unmet medical need to increase access to genomic testing to afford treatment options, particularly to older AML patients in the real‐world setting, in this new era of targeted therapies. |
format | Online Article Text |
id | pubmed-10524030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105240302023-09-28 Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system Byrd, John C. Gatz, Jennifer L. Louis, Cynthia Lim Mims, Alice S. Borate, Uma Yocum, Ashley O. Gana, Theophilus J. Burd, Amy Cancer Med RESEARCH ARTICLES BACKGROUND: We evaluated the frequency of genomic testing and treatment patterns by age category in patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated in both academic‐ and community‐based health systems within a single Midwestern State. METHODS: Retrospective analysis of data from the Indiana University Health System Enterprise Data Warehouse and two local cancer registries, of 629 patients aged ≥18 years with ND AML during 2011–2018. Primary outcome variables were, proportion of patients with genomic analysis and frequency of mutations. Chemotherapy was categorized as “standard induction” or “other chemotherapy”/targeted therapy, and hypomethylating agents. RESULTS: Overall, 13% of ND AML patients between 2011 and 2018 had evidence of a genomic sequencing report with a demonstrated increase to 37% since 2016. Genomic testing was more likely performed in patients: aged ≤60 years than >60 years (45% vs. 30%; p = 0.03), treated in academic versus community hospitals (44% vs. 26%; p = 0.01), and in chemotherapy recipients than non‐therapy recipients (46% vs. 19%; p < 0.001). Most common mutations were ASXL1, NPM1, and FLT3. Patients ≥75 years had highest proportion (46%) of multiple (≥3) mutations. Overall, 31.2% of patients with AML did not receive any therapy for their disease. This subgroup was older than chemotherapy recipients (mean age: 71.4 vs. 55.7 years, p < 0.001), and was highest (66.2%) in patients ≥75 years. CONCLUSIONS: Our results highlight the unmet medical need to increase access to genomic testing to afford treatment options, particularly to older AML patients in the real‐world setting, in this new era of targeted therapies. John Wiley and Sons Inc. 2023-08-28 /pmc/articles/PMC10524030/ /pubmed/37635639 http://dx.doi.org/10.1002/cam4.6442 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Byrd, John C. Gatz, Jennifer L. Louis, Cynthia Lim Mims, Alice S. Borate, Uma Yocum, Ashley O. Gana, Theophilus J. Burd, Amy Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system |
title | Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system |
title_full | Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system |
title_fullStr | Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system |
title_full_unstemmed | Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system |
title_short | Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system |
title_sort | real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524030/ https://www.ncbi.nlm.nih.gov/pubmed/37635639 http://dx.doi.org/10.1002/cam4.6442 |
work_keys_str_mv | AT byrdjohnc realworldgenomictestingandtreatmentpatternsofnewlydiagnosedadultacutemyeloidleukemiapatientswithinacomprehensivehealthsystem AT gatzjenniferl realworldgenomictestingandtreatmentpatternsofnewlydiagnosedadultacutemyeloidleukemiapatientswithinacomprehensivehealthsystem AT louiscynthialim realworldgenomictestingandtreatmentpatternsofnewlydiagnosedadultacutemyeloidleukemiapatientswithinacomprehensivehealthsystem AT mimsalices realworldgenomictestingandtreatmentpatternsofnewlydiagnosedadultacutemyeloidleukemiapatientswithinacomprehensivehealthsystem AT borateuma realworldgenomictestingandtreatmentpatternsofnewlydiagnosedadultacutemyeloidleukemiapatientswithinacomprehensivehealthsystem AT yocumashleyo realworldgenomictestingandtreatmentpatternsofnewlydiagnosedadultacutemyeloidleukemiapatientswithinacomprehensivehealthsystem AT ganatheophilusj realworldgenomictestingandtreatmentpatternsofnewlydiagnosedadultacutemyeloidleukemiapatientswithinacomprehensivehealthsystem AT burdamy realworldgenomictestingandtreatmentpatternsofnewlydiagnosedadultacutemyeloidleukemiapatientswithinacomprehensivehealthsystem |